Am Fam Physician. 2023;108(3):online
Author disclosure: No relevant financial relationships.
Details for This Review
Study Population: 45,049 adult tobacco smokers who were willing to quit; varenicline (Chantix) studies were conducted in the United States and other countries, whereas cytisine studies were conducted in countries other than the United States; all studies were conducted in middle- and high-income countries and included inpatient and various outpatient settings
Efficacy End Points: Smoking abstinence at longest follow-up (six months or more)
Harm End Points: Serious adverse events, neuropsychiatric serious adverse events, and cardiac serious adverse events
| Benefits | Harms |
|---|---|
| Cytisine (not available in the United States) vs. placebo | |
| 1 in 22 was abstinent from smoking at longest follow-up (six months or more) | No significant difference in rates of serious adverse events |
| Varenicline (Chantix) vs. placebo | |
| 1 in 8 was abstinent from smoking at longest follow-up (six months or more) | 1 in 166 experienced serious adverse events |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
